Figure 5 | Hypertension Research

Figure 5

From: Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia

Figure 5

(a) Changes in urinary 8-hydroxydeoxyguanosine (8-OHdG) with uric acid-lowering drugs: −0.3±4.9 (n=19 in febuxostat (Feb)), −0.7±5.3 (n=19 in Feb/Ben) and −2.2±6.4 (n=18 in benzbromarone (Ben)); *P<0.05 vs. Feb. (b) Changes in the clearance of liver-type fatty acid-binding protein (LFABP) with uric acid-lowering drugs: −0.7±5.0 (n=6 in Feb), −3.5±5.6 (n=4 in Feb/Ben), −5.1±6.3 (n=5 in Ben). (c) Changes in the clearance of flow-mediated dilation (FMD) with uric acid-lowering drugs: 0.4±1.9 (n=20 in Feb), 1.3±2.8 (n=20 in Feb/Ben) and 1.1±3.3 (n=20 in Ben).

Back to article page